AHPBA/AJCC consensus conference on staging of hepatocellular carcinoma: consensus statement.
作者信息
Henderson J M, Sherman M, Tavill A, Abecassis M, Chejfec G, Gramlich T
机构信息
Department of General Surgery, Cleveland Clinic Foundation, Cleveland, OH 44195, USA.
出版信息
HPB (Oxford). 2003;5(4):243-50. doi: 10.1080/13651820310015833.
Abstract
摘要
相似文献
1
AHPBA/AJCC consensus conference on staging of hepatocellular carcinoma: consensus statement.AHPBA/AJCC肝细胞癌分期共识会议：共识声明
HPB (Oxford). 2003;5(4):243-50. doi: 10.1080/13651820310015833.
2
AHPBA/AJCC consensus conference on staging of hepatocellular carcinoma: rationale and overview of the conference.AHPBA/AJCC肝细胞癌分期共识会议：会议的基本原理与概述
HPB (Oxford). 2003;5(4):238-42. doi: 10.1080/13651820310015824.
3
Summary of the 2010 AHPBA/SSO/SSAT Consensus Conference on HCC.2010年肝癌AHPBA/SSO/SSAT共识会议总结
Int J Hepatol. 2011;2011:565060. doi: 10.4061/2011/565060. Epub 2011 May 17.
4
Validation of the American Joint Committee on Cancer eighth edition staging system in patients undergoing hepatectomy for hepatocellular carcinoma: a US population-based study.美国癌症联合委员会第八版分期系统在接受肝细胞癌肝切除术患者中的验证：一项基于美国人群的研究。
J Surg Res. 2018 Feb;222:55-68. doi: 10.1016/j.jss.2017.09.044. Epub 2017 Nov 1.
5
Prognostic value of the 7th edition of the AJCC staging system as a clinical staging system in patients with hepatocellular carcinoma.第 7 版 AJCC 分期系统作为肝癌临床分期系统的预后价值。
Eur J Cancer. 2011 Nov;47(17):2568-75. doi: 10.1016/j.ejca.2011.07.002. Epub 2011 Aug 9.
6
Concordance and Reproducibility of Melanoma Staging According to the 7th vs 8th Edition of the .第 7 版与第 8 版 AJCC 黑色素瘤分期的一致性和可重复性。
JAMA Netw Open. 2018 May;1(1). doi: 10.1001/jamanetworkopen.2018.0083.
7
Outcomes of liver transplantation in 490 patients with hepatocellular carcinoma: validation of a uniform staging after surgical treatment.490例肝细胞癌患者肝移植的结果：手术治疗后统一分期的验证
J Am Coll Surg. 2007 May;204(5):1016-27; discussion 1027-8. doi: 10.1016/j.jamcollsurg.2006.12.043.
8
AHPBA/SSO/SSAT Consensus Conference on Resectable and Borderline Resectable Pancreatic Cancer: rationale and overview of the conference.关于可切除及临界可切除胰腺癌的AHPBA/SSO/SSAT共识会议：会议的基本原理及概述
Ann Surg Oncol. 2009 Jul;16(7):1725-6. doi: 10.1245/s10434-009-0409-5. Epub 2009 Apr 24.
9
Staging of hepatocellular carcinoma: assessment of the Japanese TNM and AJCC/UICC TNM systems in a cohort of 13,772 patients in Japan.肝细胞癌的分期：对日本13772例患者队列中日本TNM和AJCC/UICC TNM系统的评估
Ann Surg. 2007 Jun;245(6):909-22. doi: 10.1097/01.sla.0000254368.65878.da.
10
Consensus Conference on North American Training in Hepatopancreaticobiliary Surgery: A Review of the Conference and Presentation of Consensus Statements.北美肝胆胰外科培训共识会议：会议综述及共识声明介绍
Ann Surg Oncol. 2016 Jul;23(7):2153-60. doi: 10.1245/s10434-016-5111-9. Epub 2016 Mar 1.
引用本文的文献
1
Clinical Characteristics and Survival of Hepatocellular Carcinoma: Insights from Single-Centre Experience in Saudi Arabia.肝细胞癌的临床特征与生存情况：沙特阿拉伯单中心经验的见解
Cureus. 2024 Jan 20;16(1):e52608. doi: 10.7759/cureus.52608. eCollection 2024 Jan.
2
Bioengineered Ionic Liquid for Catheter-Directed Tissue Ablation, Drug Delivery, and Embolization.生物工程离子液体在导管引导的组织消融、药物输送和栓塞中的应用。
Adv Mater. 2024 Jun;36(23):e2309412. doi: 10.1002/adma.202309412. Epub 2024 Feb 16.
3
Serum Albumin Levels Relation to Tumor Aggressiveness in Patients with Hepatocellular Carcinoma from a Tertiary Care Hospital in Pakistan.巴基斯坦一家三级护理医院的肝细胞癌患者血清白蛋白水平与肿瘤侵袭性的关系
Middle East J Dig Dis. 2023 Jul;15(3):203-206. doi: 10.34172/mejdd.2023.345. Epub 2023 Jul 30.
4
Prognostic impact of tumor size on isolated hepatocellular carcinoma without vascular invasion may have age variance.肿瘤大小对无血管侵犯的孤立性肝细胞癌的预后影响可能存在年龄差异。
Front Surg. 2023 Jan 6;9:988484. doi: 10.3389/fsurg.2022.988484. eCollection 2022.
5
Expert Insights on Current Treatments for Hepatocellular Carcinoma: Clinical and Molecular Approaches and Bottlenecks to Progress.肝细胞癌当前治疗方法的专家见解：临床与分子方法及进展瓶颈
J Hepatocell Carcinoma. 2022 Dec 7;9:1247-1261. doi: 10.2147/JHC.S383922. eCollection 2022.
6
Lymphovascular invasion: A non-sized T descriptor for stage IA non-small cell lung cancer.脉管侵犯：IA 期非小细胞肺癌的非大小 T 描述符。
Thorac Cancer. 2022 Sep;13(17):2413-2420. doi: 10.1111/1759-7714.14530. Epub 2022 Jun 7.
7
Critical appraisal of TNM versus HKU staging system for postoperative prognostic evaluation of hepatocellular carcinoma.对TNM分期系统与香港大学分期系统用于肝细胞癌术后预后评估的批判性评价。
Ann Transl Med. 2021 Jun;9(11):919. doi: 10.21037/atm-20-7611.
8
Expression of CD38 on Macrophages Predicts Improved Prognosis in Hepatocellular Carcinoma.CD38 在巨噬细胞上的表达可预测肝细胞癌的预后改善。
Front Immunol. 2019 Sep 4;10:2093. doi: 10.3389/fimmu.2019.02093. eCollection 2019.
9
Utility of scoring systems combining the product of tumor number and size with liver function for predicting the prognosis of patients with hepatocellular carcinoma after hepatectomy.将肿瘤数量与大小的乘积与肝功能相结合的评分系统在预测肝细胞癌患者肝切除术后预后中的应用。
Oncol Lett. 2019 Oct;18(4):3903-3913. doi: 10.3892/ol.2019.10688. Epub 2019 Jul 29.
10
The 7th/8th American Joint Committee on Cancer and the Modified Union for International Cancer Control Staging System for Hepatocellular Carcinoma.第七届/第八届美国癌症联合委员会及改良国际癌症控制联盟肝细胞癌分期系统
Yonsei Med J. 2019 Feb;60(2):140-147. doi: 10.3349/ymj.2019.60.2.140.
本文引用的文献
1
Hepatocellular carcinoma: diagnosis and treatment.肝细胞癌：诊断与治疗
Gastroenterology. 2002 May;122(6):1609-19. doi: 10.1053/gast.2002.33411.
2
Construction of the Chinese University Prognostic Index for hepatocellular carcinoma and comparison with the TNM staging system, the Okuda staging system, and the Cancer of the Liver Italian Program staging system: a study based on 926 patients.肝细胞癌中国大学预后指数的构建及其与TNM分期系统、奥田分期系统和意大利肝癌治疗方案分期系统的比较：一项基于926例患者的研究
Cancer. 2002 Mar 15;94(6):1760-9. doi: 10.1002/cncr.10384.
3
Simplified staging for hepatocellular carcinoma.肝细胞癌的简化分期
J Clin Oncol. 2002 Mar 15;20(6):1527-36. doi: 10.1200/JCO.2002.20.6.1527.
4
Prognostic prediction and treatment strategy in hepatocellular carcinoma.肝细胞癌的预后预测与治疗策略
Hepatology. 2002 Mar;35(3):519-24. doi: 10.1053/jhep.2002.32089.
5
Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver.肝细胞癌的临床管理。2000年巴塞罗那欧洲肝脏研究学会（EASL）会议结论。欧洲肝脏研究协会
J Hepatol. 2001 Sep;35(3):421-30. doi: 10.1016/s0168-8278(01)00130-1.
6
Discrimination value of the new western prognostic system (CLIP score) for hepatocellular carcinoma in 662 Japanese patients. Cancer of the Liver Italian Program.新的西方预后系统（CLIP评分）对662例日本肝细胞癌患者的判别价值。意大利肝癌研究项目。
Hepatology. 2001 Sep;34(3):529-34. doi: 10.1053/jhep.2001.27219.
7
AJCC/TNM cancer staging, present and future.美国癌症联合委员会/国际抗癌联盟癌症分期体系的现状与未来
J Surg Oncol. 2001 Aug;77(4):233-6. doi: 10.1002/jso.1101.
8
Prospective validation of the CLIP score: a new prognostic system for patients with cirrhosis and hepatocellular carcinoma. The Cancer of the Liver Italian Program (CLIP) Investigators.CLIP评分的前瞻性验证：一种用于肝硬化和肝细胞癌患者的新预后系统。意大利肝癌研究项目（CLIP）研究人员。
Hepatology. 2000 Apr;31(4):840-5. doi: 10.1053/he.2000.5628.
9
Prognosis of hepatocellular carcinoma: the BCLC staging classification.肝细胞癌的预后：BCLC分期分类
Semin Liver Dis. 1999;19(3):329-38. doi: 10.1055/s-2007-1007122.
10
Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials.未经治疗的非手术性肝细胞癌的自然病史：治疗试验设计与评估的基本原理
Hepatology. 1999 Jan;29(1):62-7. doi: 10.1002/hep.510290145.
Zotero 插件